Allozyne

About:

Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.

Website: http://www.allozyne.com

Top Investors: Alexandria Real Estate Equities, MPM Capital, ARCH Venture Partners, Amgen Ventures, OVP Venture Partners

Description:

Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.